Exelixis initiated with a Buy at H.C. Wainwright - $EXEL H.C. Wainwright analyst Michael King initiated coverage of Exelixis with a Buy rating and $47 price target. The company is a market leader in various solid tumors, led by the rapidly evolving fields of renal cell carcinoma and hepatocellular carcinoma, King tells investors in a research note. The analyst says Exelixis promises to expand its cabozantinib franchise by garnering further label expansions.Our Take: "On our trading list and one of our more promising picks. Strong support at the $20-22 level. Trade idea: Sell some puts". $EXEL, Exelixis, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .